Physician profile
Mark Koenig
NPI 1831252964
$16,494.29
in general payments reported to CMS, 2019-2025
36 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $2,564 · 2021: $2,310 · 2022: $2,425 · 2023: $2,139 · 2024: $2,120 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,123.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,986.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,797.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,069.00 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,702.91 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $923.50 | 2021-2025 | |
| Novo Nordisk INC | $815.68 | 2019-2025 | Ozempic |
| Pfizer INC. | $753.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $661.13 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $536.03 | 2019-2022 | |
| Abbott Laboratories | $400.84 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Optinose US, INC. | $390.96 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $389.10 | 2024-2025 | Dupixent |
| Allergan, INC. | $348.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $283.16 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $272.12 | 2020-2023 | Injectafer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $203.80 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $121.16 | 2023 | Quviviq |
| Heartflow, INC. | $112.41 | 2025 | |
| Intuity Medical INC | $105.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.84 | 2023-2024 | |
| Philips North America LLC | $60.51 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.50 | 2019-2022 | |
| Astellas Pharma US INC | $51.50 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $46.35 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $38.16 | 2019-2021 | |
| Corcept Therapeutics | $37.28 | 2025 | Korlym |
| Shield Therapeutics INC | $33.85 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $29.43 | 2020 | |
| Inspire Medical Systems, INC. | $28.04 | 2023 | Inspire |
| Sumitomo Pharma America, INC. | $25.87 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $24.67 | 2025 | Nexletol |
| Baxter Healthcare | $23.89 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Genzyme Corporation | $23.25 | 2023 | |
| Sunovion Pharmaceuticals INC. | $19.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.51 | 2020 | |
| Lundbeck LLC | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.